Skip to main content
Journal cover image

Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.

Publication ,  Journal Article
Naranjo, A; Parisi, MT; Shulkin, BL; London, WB; Matthay, KK; Kreissman, SG; Yanik, GA
Published in: Pediatr Blood Cancer
July 1, 2011

BACKGROUND: ¹²³I-metaiodobenzylguanidine (MIBG) scans are preferable to ¹³¹I-MIBG for neuroblastoma imaging as they deliver less patient radiation yet have greater sensitivity in disease detection. Both ¹²³I-MIBG and ¹³¹I-MIBG scans were used for disease assessments of neuroblastoma patients enrolled on Children's Oncology Group (COG) high-risk study A3973. The hypothesis was that ¹²³I-MIBG and ¹³¹I-MIBG scans were sufficiently similar for clinical purposes in terms of ability to predict survival. PROCEDURE: Patients enrolled on COG A3973 with stage 4 disease who completed ¹²³I-MIBG or ¹³¹I-MIBG scans at diagnosis, post-induction, post-transplant, or post-biotherapy were analyzed. The performance of the Curie score for each MIBG scan type in predicting survival was evaluated. At each time point, survival curves for ¹²³I-MIBG versus ¹³¹I-MIBG were compared using the log-rank test. RESULTS: Of the 413 patients on A3973 with at least one MIBG scan, 350 were stage 4. The 5-year event-free survival (EFS) and overall survival (OS) rates were 33.4 ± 3.6% and 45.6 ± 4.0% (N = 350). At post-induction, EFS (P = 0.3501) and OS (P = 0.5337) for ¹²³I-MIBG versus ¹³¹I-MIBG were not significantly different. Similarly, comparisons at the three other time points were non-significant. CONCLUSIONS: We found no evidence of a statistically significant difference in outcome by type of scan. For future survival analyses of MIBG Curie scores, ¹²³I-MIBG and ¹³¹I-MIBG results may be combined and analyzed overall, without adjustment for scan type.

Duke Scholars

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

July 1, 2011

Volume

56

Issue

7

Start / End Page

1041 / 1045

Location

United States

Related Subject Headings

  • Young Adult
  • Vincristine
  • Treatment Outcome
  • Transplantation, Autologous
  • Survival Rate
  • Stem Cell Transplantation
  • Remission Induction
  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Oncology & Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Naranjo, A., Parisi, M. T., Shulkin, B. L., London, W. B., Matthay, K. K., Kreissman, S. G., & Yanik, G. A. (2011). Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer, 56(7), 1041–1045. https://doi.org/10.1002/pbc.22991
Naranjo, Arlene, Marguerite T. Parisi, Barry L. Shulkin, Wendy B. London, Katherine K. Matthay, Susan G. Kreissman, and Gregory A. Yanik. “Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.Pediatr Blood Cancer 56, no. 7 (July 1, 2011): 1041–45. https://doi.org/10.1002/pbc.22991.
Journal cover image

Published In

Pediatr Blood Cancer

DOI

EISSN

1545-5017

Publication Date

July 1, 2011

Volume

56

Issue

7

Start / End Page

1041 / 1045

Location

United States

Related Subject Headings

  • Young Adult
  • Vincristine
  • Treatment Outcome
  • Transplantation, Autologous
  • Survival Rate
  • Stem Cell Transplantation
  • Remission Induction
  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Oncology & Carcinogenesis